Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSAIC: Midostaurin + Gemtuzumab Ozogamicin in AML
NCT04385290Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2020
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midostaurin, gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Sep 2020; status: recruiting.
02
Drugs
midostauringemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04385290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385290.